Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723
Poulos C, Bahl R, Whittington D, Bhan MK, Clemens JD, Acosta CJ. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community. J Health Popul Nutr. 2004 Jan 1;22(3):311-21.
Bahl R, Sinha A, Poulos C, Whittington D, Sazawal S, Kumar R, Mahalanabis D, Acosta CJ, Clemens JD, Bhan MK. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J Health Popul Nutr. 2004 Jan 1;22(3):304-10.
Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.
Wolfinger RD, Gibson G, Wolfinger ED, Bennett L, Hamadeh H, Bushel P, Afshari C, Paules RS. Assessing gene significance from cDNA microarray expression data via mixed models. J Comput Biol. 2001 Jan 1;8(6):625-37.
Pladevall M, Arana A, Varas-Lorenzo C. Systematic reviews and meta-analyses in ischemic cardiopathy. Cardiovasc Risk Fact. 2000;4:270-81.
Pladevall-Vila M, Arana A, Varas-Lorenzo C. Systematic reviews and meta-analysis on coronary heart disease. (Revisiones sistemáticas y meta-análisis en cardiopatía isquemica). Cardiovasc Risk Fact. 2000;4:270-81.